If you have been reading about FSFI endpoint and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-19. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
== Distribution and habitat == The fool's mushroom grows in European woodlands and hardwood forests in springtime as the fungus' Latin name (Amanita verna or spring destroying angel) suggests. Unlike various closely related poisonous amanitas, this mushroom is not known to occur in North America.
== Chemical properties == The perchlorate ion is the least redox reactive of the generalized chlorates. Perchlorate contains chlorine in its highest oxidation number (+7). A table of reduction potentials of the four chlorates shows that, contrary to expectation, perchlorate in aqueous solution is the weakest oxidant among the four.
== Occurrence and applications == Many carboxylic acids are produced industrially on a large scale. They are also frequently found in nature. Esters of fatty acids are the main components of lipids and polyamides of aminocarboxylic acids are the main components of proteins. Carboxylic acids are used in the production of polymers, pharmaceuticals, solvents, and food additives. Industrially important carboxylic acids include acetic acid (component of vinegar, precursor to solvents and coatings), acrylic and methacrylic acids (precursors to polymers, adhesives), adipic acid (polymers), citric acid (a flavor and preservative in food and beverages), ethylenediaminetetraacetic acid (chelating agent), fatty acids (coatings), maleic acid (polymers), propionic acid (food preservative), terephthalic acid (polymers). Important carboxylate salts are soaps.
Sources: en.wikipedia.org
Presidential elections were held in the United States on November 5, 2024. The Republican ticket of former president Donald Trump and Ohio junior senator JD Vance defeated the Democratic ticket of incumbent vice president Kamala Harris and Minnesota governor Tim Walz. The incumbent president, Joe Biden of the Democratic Party, initially ran for re-election, easily sweeping aside a challenge from Democratic representative Dean Phillips of Minnesota in the Democratic primaries to become the party's presumptive nominee. However, what was broadly considered a poor debate performance in June 2024 intensified concerns about his age and health, and led to calls within his party for him to leave the race. After initially declining to do so, Biden ultimately withdrew from the race on July 21, 2024, becoming the first eligible incumbent president to run but subsequently withdraw since Lyndon B. Johnson in 1968. Biden immediately endorsed Harris, who officially became the party's presidential nominee on August 5 and the first presidential nominee who did not participate in the primaries since Vice President Hubert Humphrey in 1968. Harris selected Walz as her running mate. Trump, who lost the 2020 presidential election to Biden, ran for reelection to a nonconsecutive second term. Trump became the presumptive Republican Party's presidential nominee on March 12, 2024, easily defeating challengers such as former South Carolina governor Nikki Haley and Florida governor Ron DeSantis in the Republican primaries. He was shot in the ear in an assassination attempt on July 13, 2024.
In contrast, each Theater Command is intended to function as a unified entity with joint operations across different military branches. The PLA on 1 August 2017 marked its 90th anniversary. Before the big anniversary it mounted its biggest parade yet and the first outside of Beijing, held in the Zhurihe Training Base in the Northern Theater Command (within the Inner Mongolia Autonomous Region). In December 2023, Reuters reported a military leadership purge after high-ranking generals were ousted from the National People's Congress. Prior to 2017, over sixty generals were investigated and sacked.
An allosteric site is a site on an enzyme, unrelated to its active site, which can bind an effector molecule. This interaction is another mechanism of enzyme regulation. Allosteric modification usually happens in proteins with more than one subunit. Allosteric interactions are often present in metabolic pathways and are beneficial in that they allow one step of a reaction to regulate another step. They allow an enzyme to have a range of molecular interactions, other than the highly specific active site.
Sources: en.wikipedia.org
=== Art books === Angoisse (Philéas Fogg, 2002) Reconstitutions (Philéas Fogg, 2003). Bringing together the restaged photographs of Actualités and Quotidien. Amérique (Léo Scheer, 2006). Photographs from American towns sharing names with world cities. Fictions (P.O.L, 2006). "Enigmatic" groups of black-clad people against a black background [1][2]
The Original Mels chain has 22 locations across Northern California and Nevada. There are some Northern California locations that share the same general American Graffiti nostalgia theme and the similarly styled Mel's logo.
The first submarine not relying on human power for propulsion was the French Plongeur (Diver), launched in 1863, which used compressed air at 1,200 kPa (180 psi). Narcís Monturiol designed the first air-independent and combustion-powered submarine, Ictíneo II, which was launched in Barcelona, Spain in 1864. The submarine became feasible as potential weapon with the development of the Whitehead torpedo, designed in 1866 by British engineer Robert Whitehead, the first practical self-propelled torpedo. The spar torpedo that had been developed earlier by the Confederate States Navy was considered to be impracticable, as it was believed to have sunk both its intended target, and H. L. Hunley, the submarine that deployed it. The Irish inventor John Philip Holland built a model submarine in 1876 and in 1878 demonstrated the Holland I prototype. This was followed by a number of unsuccessful designs. In 1896, he designed the Holland Type VI submarine, which used internal combustion engine power on the surface and electric battery power underwater. Launched on 17 May 1897 at Navy Lt. Lewis Nixon's Crescent Shipyard in Elizabeth, New Jersey, Holland VI was purchased by the United States Navy on 11 April 1900, becoming the Navy's first commissioned submarine, christened USS Holland. Discussions between the English clergyman and inventor George Garrett and the Swedish industrialist Thorsten Nordenfelt led to the first practical steam-powered submarines, armed with torpedoes and ready for military use.
=== In nuclear reactors === Two major protactinium isotopes, 231Pa and 233Pa, are produced from thorium in nuclear reactors; both are undesirable and are usually removed, thereby adding complexity to the reactor design and operation. In particular, 232Th, via (n, 2n) reactions, produces 231Th, which quickly decays to 231Pa (half-life 25.5 hours). The last isotope, while not a transuranic waste, has a long half-life of 32,760 years, and is a major contributor to the long-term radiotoxicity of spent nuclear fuel. Protactinium-233 is formed upon neutron capture by 232Th. It either further decays to 233U, or captures another neutron and converts into the non-fissile 234U. 233Pa has a relatively long half-life of 27 days and high cross section for neutron capture (the so-called "neutron poison"). Thus, instead of rapidly decaying to the useful 233U, a significant fraction of 233Pa converts to non-fissile isotopes and consumes neutrons, degrading reactor efficiency. To limit the loss of neutrons, 233Pa is extracted from the active zone of thorium molten salt reactors during their operation, so that it can only decay into 233U. Extraction of 233Pa is achieved using columns of molten bismuth with lithium dissolved in it. In short, lithium selectively reduces protactinium salts to protactinium metal, which is then extracted from the molten-salt cycle, while the molten bismuth is merely a carrier, selected due to its low melting point of 271 °C, low vapor pressure, good solubility for lithium and actinides, and immiscibility with molten halides.
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.